Send to

Choose Destination
Ann N Y Acad Sci. 2006 Oct;1079:310-2.

Feasibility of a type 1 diabetes primary prevention trial using 2000 IU vitamin D3 in infants from the general population with increased HLA-associated risk.

Author information

Winnipeg DVD Study Group, and Department of Pediatrics and Child Health, University of Manitoba, 685 William Avenue, Winnipeg, MB, Canada R3E 0Z2.


Recent epidemiologic, immunologic, and NOD mouse studies suggest that intervention in the vitamin D system may be a successful method to prevent type 1 diabetes. Newborns at increased HLA-associated risk are randomized to receive either 400 or 2000 IU vitamin D3 by 1 month of age. We show that recruitment of babies from the general population for identification of HLA-associated risk status followed by enrollment to a randomized controlled prevention trial is feasible in Canada.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center